OC
TXG icon

Oppenheimer & Co’s 10x Genomics TXG Stock Holding History

Oppenheimer & Co’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,184
Closed -$213K – 1742
2025
Q3 		$213K Buy
+18,184
New +$237K ﹤0.01% 1522
2024
Q4 		– Sell
-17,294
Closed -$390K – 1649
2024
Q3 		$390K Sell
17,294
-6,745
-28% -$139K 0.01% 1130
2024
Q2 		$468K Buy
24,039
+13,456
+127% +$352K 0.01% 1021
2024
Q1 		$397K Sell
10,583
-3,537
-25% -$155K 0.01% 1076
2023
Q4 		$790K Buy
14,120
+3,588
+34% +$156K 0.01% 796
2023
Q3 		$434K Sell
10,532
-182
-2% -$9.47K 0.01% 996
2023
Q2 		$598K Sell
10,714
-145
-1% -$7.85K 0.01% 913
2023
Q1 		$606K Sell
10,859
-5,881
-35% -$275K 0.01% 872
2022
Q4 		$610K Sell
16,740
-3,280
-16% -$107K 0.01% 855
2022
Q3 		$570K Buy
20,020
+9,973
+99% +$380K 0.01% 845
2022
Q2 		$455K Buy
10,047
+2,244
+29% +$116K 0.01% 951
2022
Q1 		$594K Buy
+7,803
New +$683K 0.01% 939

Other funds holding TXG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oppenheimer & Co's TXG Position: Q4 2025 in Review

Oppenheimer & Co sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 18,184 shares — an estimated $213K sold.

Oppenheimer & Co first reported a position in TXG in Q1 2022 and held it in 12 quarters. The position peaked at $790K in Q4 2023. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

  • Oppenheimer & Co reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
  • Oppenheimer & Co sold 18,184 10x Genomics shares in Q4 2025, an estimated $213K.
  • Oppenheimer & Co first reported a position in 10x Genomics in Q1 2022 and held it in 12 quarters.
  • Oppenheimer & Co's 10x Genomics position peaked at $790K in Q4 2023.
  • 322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on Oppenheimer & Co's 13F filing for Q4 2025, filed 2 Feb 2026.